Malcolm Lloyd-Smith Insider Trading $NBIX NEUROCRINE BIOSCIENCES INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Malcolm Lloyd-Smith.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Malcolm Lloyd-Smith. Malcolm Lloyd-Smith is Chief Regulatory Officer in NEUROCRINE BIOSCIENCES INC ($NBIX) and SVP, Reg Affairs, Qual & Clin in CADENCE PHARMACEUTICALS INC ($CADX).
Malcolm Lloyd-Smith in NEUROCRINE BIOSCIENCES INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Malcolm Lloyd-Smith: Chief Regulatory Officer
Holdings: 33,610 shares
Current Value: $1,465,396
Latest Transaction: Feb 12 2021
$NBIX Market Capitalization: $3.81B
$NBIX Previous Close: $43.60
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Malcolm Lloyd-Smith in NEUROCRINE BIOSCIENCES INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 35.99 | 1,700 | 61,183 | 21,533 | |
| Feb 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.95 | 600 | 71,973 | 32,510 | 33.1 K to 32.5 K (-1.81 %) |
| Feb 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 600 | 21,594 | 33,110 | 32.5 K to 33.1 K (+1.85 %) |
| Feb 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.96 | 1,100 | 131,953 | 32,510 | 33.6 K to 32.5 K (-3.27 %) |
| Feb 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 1,100 | 39,589 | 33,610 | 32.5 K to 33.6 K (+3.38 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 5,314 | 0 | 5,314 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 117.63 | 31,880 | 3,750,044 | 31,880 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 116.87 | 1,015 | 118,624 | 32,510 | 33.5 K to 32.5 K (-3.03 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 116.74 | 1,490 | 173,936 | 31,597 | 33.1 K to 31.6 K (-4.50 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 116.89 | 756 | 88,369 | 30,437 | 31.2 K to 30.4 K (-2.42 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 114.15 | 865 | 98,739 | 29,675 | 30.5 K to 29.7 K (-2.83 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 35.99 | 1,100 | 39,589 | 23,233 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 32.99 | 8,958 | 295,524 | 0 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 35.99 | 8,612 | 309,946 | 24,333 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.98 | 600 | 71,985 | 29,002 | 29.6 K to 29 K (-2.03 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 600 | 21,594 | 29,602 | 29 K to 29.6 K (+2.07 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.96 | 500 | 59,980 | 29,002 | 29.5 K to 29 K (-1.69 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 500 | 17,995 | 29,502 | 29 K to 29.5 K (+1.72 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.95 | 8,958 | 1,074,512 | 29,002 | 38 K to 29 K (-23.60 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 32.99 | 8,958 | 295,524 | 37,960 | 29 K to 38 K (+30.89 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.98 | 4,601 | 552,041 | 29,002 | 33.6 K to 29 K (-13.69 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 4,601 | 165,590 | 33,603 | 29 K to 33.6 K (+15.86 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 119.99 | 4,011 | 481,259 | 29,002 | 33 K to 29 K (-12.15 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 35.99 | 4,011 | 144,356 | 33,013 | 29 K to 33 K (+13.83 %) |
| Nov 16 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 90.73 | 2,257 | 204,776 | 29,002 | 31.3 K to 29 K (-7.22 %) |
| Aug 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 118.87 | 2,257 | 268,277 | 26,971 | 29.2 K to 27 K (-7.72 %) |
| Apr 28 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 99.45 | 1,934 | 192,329 | 24,941 | 26.9 K to 24.9 K (-7.20 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 81.49 | 15,927 | 1,297,891 | 17,596 | |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 32.99 | 13,042 | 430,256 | 0 | |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 104.56 | 15,927 | 1,665,375 | 23,200 | 39.1 K to 23.2 K (-40.71 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 81.49 | 15,927 | 1,297,891 | 39,127 | 23.2 K to 39.1 K (+68.65 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 104.56 | 13,042 | 1,363,711 | 23,200 | 36.2 K to 23.2 K (-35.99 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 32.99 | 13,042 | 430,256 | 36,242 | 23.2 K to 36.2 K (+56.22 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 103.28 | 1,015 | 104,827 | 23,200 | 24.2 K to 23.2 K (-4.19 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 6,074 | 0 | 6,074 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 102.90 | 38,342 | 3,945,392 | 38,342 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 101.52 | 1,490 | 151,258 | 22,287 | 23.8 K to 22.3 K (-6.27 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 103.06 | 865 | 89,146 | 21,127 | 22 K to 21.1 K (-3.93 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 103.04 | 1,083 | 111,586 | 20,455 | 21.5 K to 20.5 K (-5.03 %) |
| Oct 16 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 9,956 | 153,820 | 0 | |
| Oct 16 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 90.85 | 9,956 | 904,487 | 19,613 | 29.6 K to 19.6 K (-33.67 %) |
| Oct 16 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 9,956 | 153,820 | 29,569 | 19.6 K to 29.6 K (+50.76 %) |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 7,712 | 0 | 7,712 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 81.05 | 41,671 | 3,377,435 | 41,671 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 83.58 | 920 | 76,894 | 19,238 | 20.2 K to 19.2 K (-4.56 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 88.13 | 603 | 53,143 | 17,508 | 18.1 K to 17.5 K (-3.33 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 88.16 | 669 | 58,976 | 16,574 | 17.2 K to 16.6 K (-3.88 %) |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 3,300 | 50,985 | 9,956 | |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 5,700 | 88,065 | 13,256 | |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 110.00 | 3,300 | 363,000 | 15,318 | 18.6 K to 15.3 K (-17.72 %) |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 3,300 | 50,985 | 18,618 | 15.3 K to 18.6 K (+21.54 %) |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 110.02 | 5,700 | 627,096 | 15,318 | 21 K to 15.3 K (-27.12 %) |
| Nov 08 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 5,700 | 88,065 | 21,018 | 15.3 K to 21 K (+37.21 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 12,250 | 0 | 12,250 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 6,150 | 0 | 6,150 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 81.49 | 34,750 | 2,831,778 | 34,750 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Payment of Exercise | F | 82.48 | 1,314 | 108,379 | 15,318 | 16.6 K to 15.3 K (-7.90 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 83.19 | 960 | 79,863 | 13,982 | 14.9 K to 14 K (-6.42 %) |
| Jan 04 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 18,084 | 279,398 | 18,956 | |
| Jan 04 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 77.52 | 18,084 | 1,401,823 | 13,017 | 31.1 K to 13 K (-58.15 %) |
| Jan 04 2018 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 18,084 | 279,398 | 31,101 | 13 K to 31.1 K (+138.93 %) |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 4,980 | 76,941 | 37,040 | |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 4,980 | 76,941 | 42,020 | |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 54.00 | 4,980 | 268,920 | 13,017 | 18 K to 13 K (-27.67 %) |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 4,980 | 76,941 | 17,997 | 13 K to 18 K (+38.26 %) |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 53.26 | 4,980 | 265,235 | 13,017 | 18 K to 13 K (-27.67 %) |
| May 23 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 4,980 | 76,941 | 17,997 | 13 K to 18 K (+38.26 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 51.23 | 204 | 10,451 | 13,017 | 13.2 K to 13 K (-1.54 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 50.41 | 12,861 | 648,323 | 13,221 | 26.1 K to 13.2 K (-49.31 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 10,600 | 0 | 10,600 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 43.24 | 76,800 | 3,320,832 | 76,800 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 44.61 | 116 | 5,175 | 1,082 | 1.2 K to 1.1 K (-9.68 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 43.15 | 727 | 31,370 | 0 | 727 to 0 (-100.00 %) |
| Sep 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 9,000 | 139,050 | 47,000 | |
| Sep 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 50.00 | 9,000 | 450,000 | 0 | 9 K to 0 (-100.00 %) |
| Sep 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 9,000 | 139,050 | 9,000 | 0 to 9 K |
| Jun 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | M | 15.45 | 9,000 | 139,050 | 56,000 | |
| Jun 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Sell | S | 50.00 | 9,000 | 450,000 | 0 | 9 K to 0 (-100.00 %) |
| Jun 02 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Buy | M | 15.45 | 9,000 | 139,050 | 9,000 | 0 to 9 K |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 35.99 | 36,400 | 1,310,036 | 36,400 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 7,700 | 0 | 7,700 |
Page: 1